// App-Quantinova.ai

: Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Patients with Sickle Cell Disease

Researchers

Presenter

  • Brinda Tammara

Principal Investigators

  • Frank E. Shafer

  • Lutz Harnisch

Medical Centers

  • Pfizer Inc, Collegeville, PA

  • Pfizer Inc, Collegeville, PA

  • Pfizer Inc., Tadworth, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Stearoyl-CoA desaturase

Drug/Treatment

  • rivipansel

  • GMI-1070

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Double Blind/Blinded

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved